Warren L, Jardillier J C, Ordentlich P
Wistar Institute of Anatomy and Biology, Philadelphia, Pennsylvania 19104.
Cancer Res. 1991 Apr 15;51(8):1996-2001.
The multiple drug-resistant human lymphoblastic leukemic cell, CEM/VLB100, in which P-glycoprotein (P-170) is overexpressed, has a lowered content of lysosomal enzymes, such as N-acetylglucosaminidase and beta-galactosidase, and the relative rates of secretion of these enzymes are significantly greater than those of its drug-sensitive counterpart, CEM. The ability of CEM/VLB100 cells to accumulate [3H]vinblastine ([3H]-VLB) is also greatly reduced. Multiple drug-resistant cells whose mode of resistance is not associated with P-170 do not have reduced enzyme content, and their rate of secretion is the same as that of their drug-sensitive parents. Linkage of drug and enzyme elimination is suggested by the observation that verapamil inhibits both the efflux of [3H]VLB and the secretion of lysosomal enzymes in CEM/VLB100 cells; the content of both [3H]VLB and enzyme increases in these cells when chronically exposed to verapamil. Further, both secretion of N-acetylglucosaminidase and efflux of [3H]VLB by CEM/VLB100 cells are enhanced by the addition of NaCl to the suspending, sucrose-containing medium. When cells have taken up [3H]VLB and are then fractionated by means of a Percoll centrifugation gradient, the distribution of drug among the various populations of vesicles is similar to that of N-acetylglucosaminidase. Losses of both enzyme and drug take place from these vesicular populations to varying degrees, when CEM/VLB100 cells are induced to secrete. It is proposed that, in a multiple drug-resistant cell such as CEM/VLB100, the presence of P-170 in the plasma membrane may, in some indirect manner, lead to increased exocytosis of lysosomal enzyme, ultimately resulting in a significant depletion of enzyme. Further, a toxic, cationic drug such as vinblastine, accumulating in lysosomes and acidic vesicles, is also eliminated from the cell by exocytosis. This pathway may supplement the known, major mode of efflux directly involving P-170.
多重耐药的人淋巴细胞白血病细胞CEM/VLB100中P-糖蛋白(P-170)过度表达,其溶酶体酶(如N-乙酰葡糖胺酶和β-半乳糖苷酶)含量降低,且这些酶的相对分泌率显著高于其药物敏感的对应细胞CEM。CEM/VLB100细胞积累[3H]长春碱([3H]-VLB)的能力也大大降低。耐药模式与P-170无关的多重耐药细胞酶含量没有降低,其分泌率与药物敏感的亲本细胞相同。观察到维拉帕米抑制CEM/VLB100细胞中[3H]VLB的外排和溶酶体酶的分泌,提示药物与酶的消除存在关联;当长期暴露于维拉帕米时,这些细胞中[3H]VLB和酶的含量均增加。此外,向悬浮的含蔗糖培养基中添加NaCl可增强CEM/VLB100细胞中N-乙酰葡糖胺酶的分泌和[3H]VLB的外排。当细胞摄取[3H]VLB后,通过Percoll离心梯度进行分级分离时,药物在不同囊泡群体中的分布与N-乙酰葡糖胺酶相似。当诱导CEM/VLB100细胞分泌时,这些囊泡群体中的酶和药物都会不同程度地损失。有人提出,在诸如CEM/VLB100这样的多重耐药细胞中,质膜中P-170的存在可能以某种间接方式导致溶酶体酶的胞吐作用增加,最终导致酶的显著消耗。此外,一种有毒的阳离子药物如长春碱,积聚在溶酶体和酸性囊泡中,也通过胞吐作用从细胞中排出。这条途径可能补充了已知的、直接涉及P-170的主要外排模式。